3 completed, 2 terminated. 3 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Terminated 2, Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow ATGen Canada Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure IMM-101, Observation - Cancer, Covid-19 | Phase 3 | Completed | Canadian Cancer Trials Group | 195 | 2020-10-01 | 2025-12-30 |
| Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy IVDD for NK cell activity in whole blood - Immunity, Innate, Colorectal Cancer | Not applicable | Terminated | ATGen Canada Inc | 396 | 2017-07-05 | 2023-01-31 |
| Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy IVDD for NK cell activity in whole blood - Immunity, Innate, Prostatic Neoplasm | Not applicable | Terminated | ATGen Canada Inc | 84 | 2017-04-04 | 2019-07-05 |
| Human Blood Specimen Collection to Evaluate Immune Cell Function Natural Killer Cell Activity Assay - Colorectal Cancer, Surgery | Completed | Ottawa Hospital Research Institute | 69 | 2016-08-01 | 2019-01-15 | |
| Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy NK Vue: NK cell activity in stimulated whole blood - Natural Killer Cell Cytokine Production | Not applicable | Completed | ATGen Canada Inc | 1081 | 2014-10-01 | 2017-08-14 |
Colorectal Neoplasms (3) · COVID-19 (1) · Neoplasms (1) · Postoperative Complications (1) · Prostatic Neoplasms (1)
IMM-101 (1) · Observation (1)
Canada (5)
Gilles Jobin, MD, FRCP (2) · Neil E Fleshner, MPH,MD,FRCSC (1) · Rebecca A Auer (1) · Rebecca C Auer, MD (1)